Needham & Company LLC restated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research note issued to investors on Monday, December 23rd, AnalystRatings.com reports. They currently have a $84.00 target price on the stock.
CRSP has been the topic of several other reports. ValuEngine raised shares of Crispr Therapeutics from a sell rating to a hold rating in a research report on Friday, November 1st. Canaccord Genuity boosted their target price on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the company a positive rating in a research report on Wednesday, November 20th. Oppenheimer raised their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an outperform rating in a report on Monday, November 25th. Wells Fargo & Co reaffirmed a buy rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. Finally, TheStreet upgraded Crispr Therapeutics from a d rating to a c rating in a research report on Monday, October 28th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $71.38.
Shares of CRSP stock traded up $2.18 during trading hours on Monday, hitting $62.53. 1,510,534 shares of the company were exchanged, compared to its average volume of 1,304,340. The business has a 50 day moving average of $66.06 and a two-hundred day moving average of $51.49. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics has a 52 week low of $29.34 and a 52 week high of $74.00. The company has a market capitalization of $3.31 billion, a PE ratio of -18.18 and a beta of 3.20.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. On average, research analysts forecast that Crispr Therapeutics will post 0.65 EPS for the current year.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock valued at $3,620,760 over the last three months. Corporate insiders own 21.40% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. NEXT Financial Group Inc grew its position in Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after acquiring an additional 549 shares during the last quarter. Benjamin Edwards Inc. raised its position in Crispr Therapeutics by 96.4% in the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after purchasing an additional 268 shares during the period. Coastal Investment Advisors Inc. bought a new stake in Crispr Therapeutics in the third quarter worth $26,000. US Bancorp DE boosted its position in Crispr Therapeutics by 553.7% during the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after buying an additional 526 shares during the period. Finally, BSW Wealth Partners bought a new position in shares of Crispr Therapeutics in the second quarter worth approximately $39,000. 49.82% of the stock is owned by institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Google Finance Portfolio
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.